Core Insights - The report indicates a significant increase in mutual fund allocations to Public Sector Undertaking (PSU) banks, reaching a three-year high of 3.7% in January 2026, up 30 basis points from 3.4% in the previous months [10][11] - Private banks also saw their weight rise to an eight-month high of 18.2% in January 2026, reflecting a monthly increase of 60 basis points and a yearly increase of 110 basis points [10][12] - The report highlights that State Bank of India (SBI) was among the top stocks with the highest month-on-month value increase, with a rise of Rs 96.6 billion [7][12] Mutual Fund Activity - In January 2026, various mutual funds showed divergent interests in SBI, with 15 funds buying and 5 funds selling the stock [11][12] - SBI Mutual Fund purchased 62.47 lakh shares of SBI, while HDFC Mutual Fund sold 35.96 lakh shares during the same period [8][12] - The report notes that several mutual funds, including Axis Mutual Fund and Aditya Birla Sun Life Mutual Fund, also increased their holdings in SBI [8][12] Sector Performance - The allocation in the BSE 200 index was reported at 4.1%, with several fund houses exceeding this allocation [11] - The top 10 stocks that experienced the maximum rise in value included SBI, Axis Bank, and ICICI Bank, indicating strong performance in the banking sector [7][12] - Mutual funds showed increased interest in sectors such as Utilities, Technology, Capital Goods, Metals, and Cement, while sectors like Consumer, Oil & Gas, and Healthcare saw a decrease in weights [10][12] ETF and Index Fund Performance - The DSP Nifty PSU Bank ETF and Mirae Asset Nifty PSU Bank ETF reported the highest returns of 30.61% in the last six months, while the SBI BSE PSU Bank Index Fund gained 28.09% [9][12] - The NIFTY PSU BANK - TRI index increased by 30.71% over the same period, reflecting strong performance in the PSU banking sector [9][12]

Core Insights - Harness Therapeutics has nominated HRN001 as its lead drug candidate for Huntington's disease, aiming for first-in-human studies in 2027 [1][5] - The company has formed a Clinical Advisory Board (CAB) to provide strategic guidance for the clinical development of HRN001 [6][8] - Dr. Andy Billinton, the Chief Scientific Officer, will present preclinical data at the CHDI Foundation Huntington's Disease Therapeutics Conference [7] Company Overview - Harness Therapeutics is a biotechnology company focused on addressing previously undruggable targets to transform treatments for neurodegenerative diseases [20] - The company utilizes its proprietary MISBA® platform technology to enable precise upregulation of target protein levels, which is crucial for developing disease-modifying therapies [20][21] - The company is based in Cambridge, UK, and has attracted leading life science investors, including Takeda Ventures and SV Health Investors' Dementia Discovery Fund [22] Product Development - HRN001 is an antisense oligonucleotide designed to upregulate FAN1, a key DNA repair nuclease, which has shown promise in slowing somatic expansion in Huntington's disease models [4][5] - Preclinical development of HRN001 will continue throughout 2026, with the goal of supporting clinical entry in 2027 [5] - The MISBA® platform is also being explored for other triplet repeat disorders and a broader pipeline of neurodegenerative diseases [5] Clinical Advisory Board - The CAB consists of leading experts in Huntington's disease, including Dr. Irina Antonijevic, Dr. Anne Rosser, and Dr. Jeffrey Long, among others [9][10] - The CAB will provide strategic guidance on clinical development, trial design, and translational strategy as the program advances [6][10] Scientific Rationale - Huntington's disease is caused by the expansion of CAG repeats in the huntingtin gene, with ongoing somatic expansion recognized as a key driver of disease progression [2][3] - FAN1 has emerged as a compelling target for suppressing somatic expansion, demonstrating a strong genetic association with disease onset [3][10]

Core Insights - Roche announced that the phase III MAJESTY study for Gazyva®/Gazyvaro® (obinutuzumab) in adults with primary membranous nephropathy met its primary endpoint, demonstrating statistically significant results in achieving complete remission at two years compared to tacrolimus [1][2] Group 1: Study Results - The MAJESTY study showed that significantly more patients achieved complete remission at 104 weeks with Gazyva/Gazyvaro compared to tacrolimus [1] - Key secondary endpoints also indicated statistically significant benefits in overall remission (complete or partial) at week 104 and complete remission at week 76 [2] Group 2: Disease Context - Primary membranous nephropathy is a chronic autoimmune condition affecting nearly 88,000 people in the EU and over 96,000 in the US, with up to 30% of patients developing kidney failure within 10 years [4][10] - The condition leads to significant health system costs and impacts on patients and families due to the need for invasive interventions like dialysis or transplant [4] Group 3: Treatment Implications - If approved, Gazyva/Gazyvaro would be the first therapy specifically indicated for primary membranous nephropathy, addressing a significant unmet need in treatment options [2][4] - The drug has shown potential in maintaining kidney function longer and preventing life-threatening complications associated with the disease [2][4] Group 4: Company Pipeline and Strategy - Gazyva/Gazyvaro is already approved for treating adults with active lupus nephritis and is being investigated in a global phase II study for children and adolescents with lupus nephritis [6] - Roche has a broad pipeline aimed at addressing immune-mediated and kidney-related diseases, with over 10 phase II-III clinical studies ongoing [11]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Vistagen Therapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Vistagen common stock between April 1, 2024, and December 16, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Background - The lawsuit alleges that Vistagen provided misleading information regarding its drug fasedienol, which is under development for treating social anxiety disorder, while concealing material adverse facts about its Phase 3 clinical trial [5][6]. - The defendants made positive assertions about the drug's trial success based on previous results, which the lawsuit claims were misleading [5].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. during the specified Class Period, indicating potential misrepresentation by the company regarding its drug candidate and regulatory approvals [1][5]. Group 1: Class Action Details - The class action lawsuit is for investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. Group 2: Allegations Against uniQure - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [5]. - It is alleged that the company's statements regarding its business operations and prospects lacked a reasonable basis, leading to investor damages when the true information became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical studies [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma provided investors with optimistic information about the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI), suggesting confidence in the drug's efficacy [5]. - Defendants allegedly made positive statements while concealing adverse facts about the Phase 3 programs, which did not meet their primary endpoints, leading to artificially inflated prices for Mereo's ADSs [6]. Group 2: Class Action Participation - Investors who purchased Mereo ADSs during the specified Class Period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against uniQure N.V. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by April 13, 2026 [4]. Group 1: Allegations Against uniQure - The complaint alleges that uniQure and its executives made false and misleading statements regarding the FDA approval of the design of the Pivotal Study and downplayed the likelihood of delays in the BLA timeline [6]. - It is claimed that the results from the Pivotal Study were not fully approved by the FDA, and the company would need to conduct additional studies to support its BLA submission [6]. - The disclosure on November 3, 2025, revealed that the FDA no longer agreed that the data from the Phase I/II AMT-130 studies would be adequate for BLA submission, contradicting previous statements about the path toward accelerated approval [7]. Group 2: Financial Impact - Following the disclosure, uniQure's share price fell by $33.40, a decline of over 49%, dropping from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [8]. Group 3: Legal Proceedings - The role of lead plaintiff in the class action is designated to the investor with the largest financial interest who is also typical of class members, with the option for any member to move the court to serve as lead plaintiff [9]. - Faruqi & Faruqi encourages anyone with information regarding uniQure's conduct to come forward, including whistleblowers and former employees [10].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 15, 2026 (GLOBE NEWSWIRE) -- Faruqi ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Vistagen Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Vistagen common stock between April 1, 2024, and December 16, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action litigation [4] Group 3: Case Background - The lawsuit alleges that Vistagen's defendants provided misleading information regarding the development and commercialization of its drug fasedienol, which is intended for treating social anxiety disorder [5] - Defendants reportedly made overly positive statements about fasedienol's trial success while concealing material adverse facts about the Phase 3 PALISADE-3 trial, leading to investor damages when the truth was revealed [6]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. during the specified Class Period, indicating potential misrepresentation and lack of disclosure regarding the company's drug candidate and regulatory approvals [1][5]. Group 1: Class Action Details - The class action lawsuit is for investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm directly [3][6]. Group 2: Allegations Against uniQure - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [5]. - It is alleged that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the true information became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].